keyword
MENU ▼
Read by QxMD icon Read
search

"peptide receptor radionuclide therapy"

keyword
https://www.readbyqxmd.com/read/28533939/efficacy-of-peptide-receptor-radionuclide-therapy-with-177-lu-octreotate-in-metastatic-pulmonary-neuroendocrine-tumors-a-dual-centre-analysis
#1
Amir Sabet, Alexander R Haug, Collin Eiden, Christoph J Auernhammer, Birgit Simon, Peter Bartenstein, Hans J Biersack, Samer Ezziddin
There is lack of data on the specific benefit of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) of pulmonary origin. This dual- centre study aimed to assess outcome and toxicity of standardized PRRT with (177)Lu-octreotate in a patient population of advanced pulmonary NET of grade 1-2. We retrospectively assessed 22 consecutively patients treated with 4 intended cycles at 3 monthly intervals (mean activity per cycle 7.8±0.68 GBq). In a median follow-up period of 54 months, no significant nephrotoxicity (≥ grade 3) was observed...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28514206/first-in-human-pet-ct-imaging-of-metastatic-neuroendocrine-neoplasms-with-cyclotron-produced-44-sc-dotatoc-a-proof-of-concept-study
#2
Aviral Singh, Nicholas P van der Meulen, Cristina Müller, Ingo Klette, Harshad R Kulkarni, Andreas Türler, Roger Schibli, Richard P Baum
(44)Sc is a promising positron emission tomography (PET) radionuclide (T1/2 = 4.04 hours, Eβ+average = 632 keV) and can be made available, using a cyclotron production route, in substantial quantities as a highly pure product. Herein, the authors report on a first-in-human PET/CT study using (44)Sc-DOTATOC prepared with cyclotron-produced (44)Sc. The production of (44)Sc was carried out through the (44)Ca(p,n)(44)Sc nuclear reaction at Paul Scherrer Institut, Switzerland. After separation, (44)Sc was shipped to Zentralklinik Bad Berka, Germany, where radiolabeling was performed, yielding radiochemically pure (44)Sc-DOTATOC...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28483790/effect-of-hormone-secretory-syndromes-on-neuroendocrine-tumor-prognosis
#3
Wouter T Zandee, Kimberly Kamp, R C S van Adrichem, R A Feelders, Wouter W de Herder
The treatment of hormone hypersecretory syndromes caused by neuroendocrine tumors (NETs) can be a major challenge. NETs originating from the small intestine often secrete serotonin causing flushing, diarrhea and valve fibrosis, leading to dehydration or heart failure in severe cases. NETs from the pancreas can secrete a wider variety of hormones, like insulin, glucagon and gastrin leading to distinct clinical syndromes. Historically mortality in patients with functioning NETs was high due to the complications caused by the hypersecretion of hormones...
May 8, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28450554/biodistribution-pharmacokinetics-and-dosimetry-of-177-lu-90-y-and-111-in-labeled-somatostatin-receptor-antagonist-ops201-in-comparison-to-the-agonist-177-lu-dota-tate-the-mass-effect
#4
Guillaume Pierre Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani
Radiolabeled somatostatin receptor (sstr) antagonists have shown in vivo higher uptake in sstr-expressing tumors than agonists. In this pre-clinical study the sstr2-antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]) labeled with (177)Lu, (90)Y and (111)In was compared with the sstr2-agonist (177)Lu-DOTA-TATE. Methods: Biodistribution, pharmacokinetics, single-photon emission computed tomography/computed tomography (SPECT/CT) and dosimetry studies were performed to assess the bioequivalence of all radiotracers...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28428192/long-term-efficacy-survival-and-safety-of-177lu-dota0-tyr3-octreotate-in-patients-with-gastroenteropancreatic-and-bronchial-neuroendocrine-tumors
#5
Tessa Brabander, Wouter A Van der Zwan, Jaap Jm Teunissen, Boen L R Kam, Richard A Feelders, Wouter W de Herder, Casper H J van Eijck, Gaston J H Franssen, Eric P Krenning, Dik J Kwekkeboom
Purpose<br /> Bronchial and gastroenteropancreatic neuroendocrine tumors (NETs) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. We have treated over 1200 patients with peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) since the year 2000 and present the results on efficacy, survival and toxicity of this therapy. <p>Patients and methods<br /> For safety analysis, 610 patients treated with a cumulative dose of at least 100 mCi (3...
April 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28405692/-pulmonary-carcinoid-tumors
#6
H Prosch
Pulmonary carcinoids are rare low-grade malignant tumors, which arise from the neuroendocrine system. Approximately 80% of all pulmonary carcinoid tumors are the relatively low-grade typical carcinoids and 20% are the more aggressive atypical carcinoids. Most carcinoids arise from the central airways and only a minority of carcinoids are found in the lung periphery. While most of the peripheral carcinoids are asymptomatic, central carcinoids are symptomatic and present with hemoptysis, wheezing or bronchial obstruction...
April 12, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28402980/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-neoplasia-peptide-receptor-radionuclide-therapy-with-radiolabeled-somatostatin-analogues
#7
Rodney J Hicks, Dik J Kwekkeboom, Eric Krenning, Lisa Bodei, Simona Grozinsky-Glasberg, Rudolf Arnold, Ivan Borbath, Jaroslaw Cwikla, Christos Toumpanakis, Greg Kaltsas, Philippa Davies, Dieter Hörsch, Eva Tiensuu Janson, John Ramage
No abstract text is available yet for this article.
April 13, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28400403/molecular-imaging-in-the-investigation-of-hypoglycaemic-syndromes-and-their-management
#8
David A Pattison, Rodney J Hicks
There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and its integration into patient management. These targets include peptide receptors - somatostatin receptors (SSTR) and glucagon-like peptide-1 receptor (GLP-1R) - the Amine Precursor Uptake and Decarboxylation system utilising the diphydroxyphenylaline (DOPA) analogue 6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine (18F-FDOPA), and glycolytic metabolism with 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)...
April 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28361189/personalized-177-lu-octreotate-peptide-receptor-radionuclide-therapy-of-neuroendocrine-tumours-a-simulation-study
#9
Michela Del Prete, François-Alexandre Buteau, Jean-Mathieu Beauregard
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-octreotate is commonly administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly variable absorbed doses to critical organs and suboptimal treatment of most patients. The primary aims of this study were to design a personalized PRRT (P-PRRT) protocol based on dosimetry, and to perform a simulation of this protocol in a retrospective cohort of patients with neuroendocrine tumours, in order to assess the potential of P-PRRT to safely increase the absorbed dose to the tumour during a four-cycle induction course...
March 31, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#10
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28319500/clinical-response-profile-of-metastatic-advanced-pulmonary-neuroendocrine-tumors-to-peptide-receptor-radionuclide-therapy-with-177lu-dotatate
#11
Rahul V Parghane, Sanjay Talole, Kumar Prabhash, Sandip Basu
OBJECTIVES: The aims of this study were to perform multiparametric response assessment of metastatic/advanced pulmonary neuroendocrine tumors (NETs) to Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) (clinical, biochemical, molecular/structural imaging, and survival assessment) and to study the relationship between response, mortality, and overall survival with dual-tracer molecular imaging parameters. METHODS: Twenty-two patients (6 women, 16 men; median age, 44 years; range, 16-72 years) of histopathologically proven pulmonary NETs with metastatic/advanced disease were included and analyzed retrospectively...
June 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28316066/long-term-results-and-tolerability-of-tandem-peptide-receptor-radionuclide-therapy-with-90-y-177-lu-dotatate-in-neuroendocrine-tumors-with-respect-to-the-primary-location-a-10-year-study
#12
Jolanta Kunikowska, Dariusz Pawlak, Marianna I Bąk, Beata Kos-Kudła, Renata Mikołajczak, Leszek Królicki
INTRODUCTION: The peptide receptor radionuclide therapy (PRRT) with (90)Y and (177)Lu is a form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET). AIM: The aim of the study was to evaluate clinical results and long-term side effects of tandem (90)Y /(177)Lu-DOTATATE therapy in patients with NET. Additionally, we evaluated clinical results with reference to the primary site. MATERIALS AND METHODS: 59 patients with disseminated NET were included in the study prospectively...
March 18, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28263217/peptide-receptor-radionuclide-therapy-with-177lu-octreotate-in-patients-with-somatostatin-receptor-expressing-neuroendocrine-tumors-six-years-assessment
#13
Mohammadali Hamiditabar, Muzammil Ali, Joseph Roys, Edward M Wolin, Thomas M OʼDorisio, David Ranganathan, Izabela Tworowska, Jonathan R Strosberg, Ebrahim S Delpassand
OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a promising treatment for patients with inoperable, well to moderately differentiated metastatic neuroendocrine tumors (NETs). In continuation of our novel study with the radionuclide lutetium Lu, we now present further results of Lu DOTATATE therapy in managing NETs and other somatostatin receptor-expressing tumors in a larger and more diverse patient group. PATIENTS AND METHODS: One hundred forty-four consecutive patients (85 men and 59 women; age range, 11-87 years; mean age, 58...
June 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28246882/safety-of-multiple-repeated-cycles-of-177-lu-octreotate-in-patients-with-recurrent-neuroendocrine-tumour
#14
Anna Yordanova, Karin Mayer, Peter Brossart, Maria A Gonzalez-Carmona, Christian P Strassburg, Markus Essler, Hojjat Ahmadzadehfar
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how many cycles of (177)Lu-octreotate can be repeated while maintaining an acceptable toxicity profile. The purpose of this study was to assess the safety of repeated PRRT in patients with recurrent NET. METHODS: We retrospectively evaluated data from 15 patients treated with repeated PRRT between 2004 and 2015...
March 1, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28229838/-treatment-of-gastroenteropancreatic-neuroendocrine-tumors-with-177lu-dota-tate-experience-of-the-portuguese-institute-of-oncology-in-porto
#15
Inês Lucena Sampaio, Henrique Vara Luiz, Liliana Sobral Violante, Ana Paula Santos, Luís Antunes, Isabel Torres, Cristina Sanches, Isabel Azevedo, Hugo Duarte
INTRODUCTION: The purpose of this article is to report the experience of the Portuguese Institute of Oncology - Porto in the treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE, regarding the safety and efficacy of this treatment modality. MATERIAL AND METHODS: A retrospective analysis of clinical reports of patients with gastroenteropancreatic neuroendocrine tumors undergoing treatment with 177Lu-DOTA-TATE between April 2011 and November 2013 was performed...
November 2016: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28220446/radionuclide-therapy-for-neuroendocrine-tumors
#16
REVIEW
Mauro Cives, Jonathan Strosberg
Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, (90)Y-DOTATOC and (177)Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared (177)Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy...
February 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28217023/metabolic-bone-disease-in-the-context-of-metastatic-neuroendocrine-tumor-differentiation-from-skeletal-metastasis-the-molecular-pet-ct-imaging-features-and-exploring-the-possible-etiopathologies-including-parathyroid-adenoma-men1-and-paraneoplastic-humoral
#17
Rohit Ranade, Sandip Basu
Three cases of metabolic bone disease in the setting of metastatic neuroendocrine tumor (NET) are illustrated with associated etiopathologies.  One of these cases harbored mixed lesions in the form of vertebral metastasis (biopsy proven) while the other skeletal lesions were caused due to metabolic bone disease related to multiple parathyroid adenomas. While the metastatic lesion was positive on 68Ga-DOTATATE positron emission tomography-computed tomography (PET-CT), the lesions of metabolic bone disease were negative and the 18F-fluoride PET-CT demonstrated the features of metabolic bone scan...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28203088/peptide-receptor-radionuclide-therapy-in-the-management-of-gastrointestinal-neuroendocrine-tumors-efficacy-profile-safety-and-quality-of-life
#18
REVIEW
Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli
Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28178157/the-prognostic-influence-of-the-proliferative-discordance-in-metastatic-pancreatic-neuroendocrine-carcinoma-revealed-by-peptide-receptor-radionuclide-therapy-case-report-and-review-of-literature
#19
Nathanaëlle Montanier, Juliette Joubert-Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, Antony Kelly
RATIONALE: Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28099254/everolimus-in-pancreatic-neuroendocrine-carcinomas-g3
#20
Francesco Panzuto, Maria Rinzivillo, Francesca Spada, Lorenzo Antonuzzo, Toni Ibrahim, Davide Campana, Nicola Fazio, Gianfranco Delle Fave
OBJECTIVE: The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3. METHODS: This was a retrospective analysis of patients with pNEC G3 and Ki67 20% to 55% treated with everolimus. RESULTS: Fifteen patients with median Ki67 30% and Eastern Cooperative Oncology Group performance status 0 to 1 were evaluated. Of these, 4 patients received everolimus as first-line treatment, whereas 11 had been pretreated with chemotherapy or peptide receptor radionuclide therapy...
March 2017: Pancreas
keyword
keyword
108898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"